Chronic Stress & Cancer: How Stress Impacts Treatment & Survival Rates

The Hidden Stress of Cancer: How Chronic Stress Impacts Treatment and Survival

Stress is an unavoidable part of the cancer journey. It begins at diagnosis, intensifies during treatment and often lingers even after therapy ends. It influences treatment decisions, fuels anxiety about results, and disrupts daily life. Emerging research reveals that chronic stress isn’t just an emotional burden; it can trigger biological processes that hinder treatment and potentially affect survival rates.

A systematic review published in January 2026 in the International Journal of Molecular Sciences by researchers at Wroclaw Medical University, underscores this connection. The study analyzed data from four common cancers – breast, prostate, pancreatic, and ovarian – categorized by five-year survival rates, to understand how chronic stress impacts outcomes.

What is Chronic Stress?

Biologically, chronic stress represents a prolonged strain on the body’s adaptive mechanisms. It’s not a fleeting reaction to a difficult event, but a sustained activation of the body’s threat response systems lasting weeks or months.

In the context of cancer, stress is multifaceted, encompassing not only anxiety and sadness but also social, professional, familial, and existential concerns. Many patients grapple with redefining their life plans, social roles, and sense of control over their bodies.

The review identifies three interconnected stages linking chronic stress to cancer progression:

1. Hormonal Alarm: Chronic stress persistently activates the hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system, leading to prolonged elevation of cortisol, adrenaline, and noradrenaline. As researcher Katarzyna Herbetko explains, “The body acts as if it were constantly in danger mode. This is associated with increased inflammation and immunosuppression, which can promote tumor progression and weaken the response to treatment.”
2. Immunity and Inflammation: Stress hormones disrupt immune function. Prolonged exposure to cortisol and catecholamines can weaken immune surveillance and promote chronic, low-grade inflammation, creating an environment where cancer cells can thrive and evade the body’s defenses.
3. Tumor Environment: At the tissue level, chronic stress can influence angiogenesis (blood vessel formation), cancer cell migration, and the development of treatment resistance.

Researchers acknowledge the difficulty in isolating the impact of stress from disease progression, treatment intensity, and other clinical factors in clinical trials.

Cancer Type Matters

The review highlights that chronic stress doesn’t affect all cancers equally. Its biological and clinical significance varies depending on the type of cancer and its prognosis.

In cancers with generally better survival rates, like breast and prostate cancer, stress often manifests as chronic uncertainty. Patients live with the disease long-term, facing fears of recurrence, treatment side effects, and lasting changes in quality of life. In these cases, adrenergic and glucocorticoid signaling play a role, potentially influencing metastasis and treatment response.

Cancers with poorer prognoses, such as pancreatic and ovarian cancer, present a different picture. These patients often experience more severe psychological distress and depression, sometimes even before diagnosis, suggesting a biological component rather than solely an emotional reaction to the disease. Inflammatory and cytokine mechanisms, including elevated IL-6 levels, are prominent in these cases.

“Psychological distress is not just an emotion, but a factor that can contribute to physiological overload of the body and reduce the reserves necessary for the treatment process.”

Katarzyna Herbetko, Faculty of Medicine, Wroclaw Medical University

The Role of Psychotherapy

The authors emphasize that psychotherapy in oncology extends beyond emotional support. Studies demonstrate that psychological interventions can:

• Reduce anxiety and depression
• Improve quality of life
• Influence stress and inflammation markers, such as cortisol levels and certain cytokines

However, researchers caution against oversimplification. “There is no simple correlation: psychotherapy = longer survival,” notes Katarzyna Herbetko. “We see real, measurable biological changes, but the current state of knowledge does not allow for clear conclusions regarding mortality.” The benefits of psychological therapy may also diminish after its completion, highlighting the need for sustained support.

Recommendations and Future Directions

The authors acknowledge limitations in the current research, including inconsistent methods for measuring stress, a lack of meta-analyses for precise conclusions, and the challenge of separating stress as a biological factor from its consequences as a result of illness and treatment.

The central message of the review is clear: chronic stress is not a patient’s fault. It’s a factor linked to measurable biological processes that, like pain, malnutrition, or sleep disorders, should be addressed clinically.

The authors propose:

• Systematic integration of psycho-oncology into standard cancer care
• Routine screening for distress with rapid access to support
• Support for partners and caregivers
• Development of digital interventions (e-health) and strategies to maintain therapeutic effects

As Katarzyna Herbetko concludes, “Psycho-oncology cannot be an add-on. Chronic stress should be treated as a modifiable risk factor in oncology, analyzed in the context of complex biological, psychological, and environmental interactions.”